Despite treatments and vaccinations, it remains difficult to develop naturally occurring COVID-19 inhibitors. Here, our main objective is to find potential lead compounds from the retrieved alkaloids with antiviral and other biological properties that selectively target the main SARS-CoV-2 protease (Mpro), which is required for viral replication. In this work, 252 alkaloids were aligned using Lipinskis rule of five and their antiviral activity was then assessed. The prediction of activity spectrum of substances (PASS) data was used to confirm the antiviral activities of 112 alkaloids. Finally, 50 alkaloids were docked with Mpro. Furthermore, assessments of molecular electrostatic potential surface (MEPS), density functional theory (DFT), and absorption, distribution, metabolism, excretion, and toxicity (ADMET) were performed, and a few of them appeared to have potential as candidates for oral administration. Molecular dynamics simulations (MDS) with a time step of up to 100ns were used to confirm that the three docked complexes were more stable. It was found that the most prevalent and active binding sites that limit Mprosactivity are PHE294, ARG298, and GLN110. All retrieved data were compared to conventional antivirals, fumarostelline, strychnidin-10-one (L-1), 2,3-dimethoxy-brucin (L-7), and alkaloid ND-305B (L-16) and were proposed as enhanced SARS-CoV-2 inhibitors. Finally, with additional clinical or necessary study, it may be able to use these indicated natural alkaloids or their analogs as potential therapeutic candidates.
1 January 2026 in Advances in Pharmacological and Pharmaceutical Sciences
Objective: Desmos chinensis (Annonaceae) is an underexplored medicinal plant from Southeast Asia with limited pharmacological validation. This study investigated, for the first time, the analgesic, anti‐pyretic, anti‐inflammatory, and anti‐arthritic potential of the methanolic extract of D. chinensis leaf and its solvent‐soluble fractions (n‐hexane, dichloromethane, and ethyl acetate) using in vivo, in vitro, and in silico approaches. Methods: Analgesic activity was assessed using the acetic acid–induced writhing method; anti‐pyretic activity was assessed using the brewer’s yeast‐induced pyrexia model; anti‐inflammatory activity was assessed using protein denaturation; and anti‐arthritic activity was assessed using the human red blood cell membrane stabilization method. Result: In the writhing test, the ME and ethyl acetate fractions at 400 mg/kg produced marked analgesic effects, with 86.36% and 65.91% inhibition of writhing, respectively, compared with diclofenac (90.45%). In the anti‐pyretic model, ME significantly reduced yeast‐induced hyperthermia, achieving up to 100% reduction in pyrexia within 4 h at 400 mg/kg ( p < 0.001). In vitro assays showed concentration‐dependent anti‐inflammatory and anti‐arthritic activities. ME inhibited protein denaturation with an IC 50 of 337.42 μg/mL, while HRBC membrane stabilization revealed strong anti‐arthritic potential with an IC 50 of 246.34 μg/mL, comparable to diclofenac sodium. Docking analysis revealed favorable interactions between phytoconstituents and inflammation‐related targets. Conclusion: This study provides the first integrated pharmacological evidence that D. chinensis leaves possess significant analgesic, anti‐pyretic, anti‐inflammatory, and anti‐arthritic activities. The quantitative efficacy and in silico findings highlight D. chinensis as a promising source of bioactive compounds, warranting further isolation, mechanistic, and preclinical investigations.